Navigation Links
ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
Date:5/2/2008

PLYMOUTH, Minn., May 2 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, today reported financial results for its fiscal first quarter of 2008 and its revised financial guidance for 2008.

As previously reported, ev3's net sales were $101.3 million in the first quarter of 2008 representing a 65% increase over the same quarter of the prior year and a 10% increase over the fourth quarter of 2007. The increase in net sales over the same quarter of the prior year was primarily attributable to the acquisition of FoxHollow. The sequential quarter increase in net sales was driven by growth in the pre-FoxHollow acquisition peripheral vascular business segment and the neurovascular business segment. However, first quarter net sales results were negatively impacted by greater than anticipated sales force integration challenges related to the FoxHollow acquisition and elevated customer inventory levels of SilverHawk products.

Robert Palmisano, president and chief executive officer of ev3 Inc., commented, "While we believe that our fundamental strategies are sound, we have much work ahead of us to improve our execution and efficiency. My top priority will be to continue expanding our position in the peripheral vascular and neurovascular markets globally by offering a full complement of innovative therapies, investing in the development of our next generation of products and pursuing a broad clinical trial agenda to bring new products to market and further validate the scientific foundation of our endovascular procedures. I believe these initiatives will in turn drive growth and shareholder value."

Palmisano commented further, "In resetting our guidance, we took into account the factors that could affect our business in 2008, including the performance of our U.S. atherectomy business, which continues to be adversely affected by elevated customer inventory levels of SilverHawk, the ability of our U.S. peripheral va
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. United Therapeutics Reports First Quarter 2008 Financial Results
2. Endocare Reports 2008 First Quarter Financial Results
3. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
4. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
5. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Alexion Reports First Quarter 2008 Results
8. Masimo Reports First Quarter 2008 Financial Results
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
11. SuperGen Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Back in the 1970’s, many companies calculated their office ... included space for circulation and file storage. “It was ... Nidea Corporate Real Estate / ITRA Global , a ... however, 250 square feet per employee became the norm. ... 175 to 225 square feet, and over the next few ...
(Date:9/29/2014)... of diagnostics today, with imaging techniques like MRI ... NMR (nuclear magnetic resonance) increasing steeply over the ... resolution and quality still limit these techniques because ... is hyperpolarization, which involves injecting the patient with ... the distribution and fate of specific molecules in ...
(Date:9/29/2014)... Research and Markets  has announced the ... & Services, End-User , Application - Global Forecast to ... The global oligonucleotide synthesis market is expected to reach ... growing at a CAGR of 9.8% from 2014 to ... the basis of products and services, applications, end users, ...
(Date:9/29/2014)... involve a range of resource and environmental problems. ... resin and a clever recycling strategy, Uppsala researchers ... alternative. Their study will be presented soon in ... think our discovery can open several doors to ... the future, says Daniel Brandell, Associate Professor at ...
Breaking Biology Technology:ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Smart, eco-friendly new battery to solve problems 2
... CAMBRIDGE, Mass., Jan. 13 Verenium Corporation,(Nasdaq: ... the development of next-generation cellulosic,ethanol and high-performance ... compliance with the continued listing requirements of ... that it had fallen out of,compliance with ...
... January 15th at 1:00PM PTNEW YORK, Jan. 13 ... announced that Michael S. Weiss, the Company,s Chairman and ... J.P. Morgan 27th Annual Healthcare Conference being held in ... Thursday, January 15th at 1:00pm PT and will be ...
... Jan. 13 Burnham Institute for Medical ... and license agreement with Johnson & Johnson ... The agreement is Burnham,s first broad-based partnership ... agreement, Burnham will provide J&JPRD with access ...
Cached Biology Technology:Verenium Regains Compliance With Nasdaq Continued Listing Requirement 2Verenium Regains Compliance With Nasdaq Continued Listing Requirement 3Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2
(Date:9/29/2014)... that the exposure to tar tended to be lower ... Similarly, exposure to nicotine tended to be lower. ... cigarette in several countries around the world. Previous studies ... in the smoke of these cigarettes are lower than ... chemicals in the smoke are not necessarily linked to ...
(Date:9/29/2014)... According to a NASA story from 2009, "human activities in ... fire emissions issue. Palm oil is increasingly grown for use ... fats in processed foods. It has become the most widely ... in recent years to surpass that of soybean oil. , ... has to be cleared to grow the crop, and the ...
(Date:9/29/2014)... team says recently identified radiation detection properties of a ... for homeland security and medical advances. , In a ... of Optics Letters , UT Arlington Physics Professor ... to fabricate transparent nanoscintillators by heating nanoparticles composed of ... formed. A scintillator refers to a material that ...
Breaking Biology News(10 mins):Slim cigarette smokers not exposed to more harmful chemicals 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... 2008The 2008 American Society for Microbiology (ASM) BD ... presented to Stephen C. Edberg, Professor, Department of ... of Medicine, and Director, Clinical Microbiology Laboratory, Yale-New ... award recognizes a distinguished scientist for research accomplishments ...
... be the first recipient of a prestigious award given by ... Meeting of the Ecological Society of America on August 3. ... an outstanding record of informing their political decision-making with ecological ... figure that has a sharp appreciation for local and global ...
... 28, 2008The 2008 American Society for Microbiology (ASM) ... is presented to Steven A. Rosenberg, Chief of ... Services University of the Health Sciences, and Professor ... and Health Sciences. Sponsored by Abbott Laboratories Diagnostics ...
Cached Biology News:American Society for Microbiology honors Stephen C. Edberg 2American Society for Microbiology honors Steven A. Rosenberg 2
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
... Nucleon HT, 1 kit. Facilitates the ... paraffin-embedded sections and hard tissue requiring proteinase ... high quality DNA from 50 preparations of ... Category: DNA/RNA Synthesis & Purification, Purification and ...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Phospho-p70 S6 Kinase (T229) Affinity Purified PAb...
Biology Products: